Sci Adv:中国研究人员开发出新型骨支架

2019-08-10 周舟 新华网

中国一个研究团队开发出一种兼具抗肿瘤和骨再生功能的承力骨替代支架,在动物实验中,不外加化疗药物即能达到良好的治疗及修复效果,将来有望使面临截肢的骨肿瘤患者接受保肢手术治疗,并提高患者的长期生存率。

中国一个研究团队开发出一种兼具抗肿瘤和骨再生功能的承力骨替代支架,在动物实验中,不外加化疗药物即能达到良好的治疗及修复效果,将来有望使面临截肢的骨肿瘤患者接受保肢手术治疗,并提高患者的长期生存率。

骨肿瘤是发生于骨骼或其附属组织的肿瘤,多发于青少年群体。恶性骨肿瘤致死致残率高,治疗过程中常因肿瘤复发或转移导致患者死亡。目前手术切除是骨肿瘤临床治疗的主要手段,但截肢手术或瘤段切除造成的终生骨缺损会导致劳动力丧失,因此在抑制局部肿瘤复发和转移的前提下,最大限度保留肢体功能是医生追求的目标。

四川大学张兴栋院士团队和四川大学华西医院骨科屠重棋教授团队在新一期美国《科学进展》杂志上发表论文介绍,他们利用3D打印技术制备出承力多孔钛支架,将“纳米羟基磷灰石”粒子负载于支架表面,并植入构建好的兔股骨原位骨肿瘤模型中。

结果显示,这种涂层支架能显著抑制实体瘤体积及其肺部转移,还能促进支架内的新骨生成,加速节段骨缺损的愈合。进一步对动物五大脏器及血液指标的检测表明,这种支架具有良好的生物安全性,极具临床应用潜能。



据介绍,支架上的“纳米羟基磷灰石”粒子可抑制骨肉瘤细胞、黑色素瘤细胞、基底癌细胞等多种肿瘤细胞的增殖,且对正常成骨细胞、骨髓基质干细胞、成纤维细胞等无毒副作用。

论文通讯作者之一、四川大学生物材料工程研究中心的杨晓对新华社记者说,该材料设计有望扩大保肢手术适应症,并减少放化疗药物用量,为临床突破骨肿瘤术后的骨缺损修复和抑制局部肿瘤复发的难题提供了新的思路。

原始出处:
Kun Zhang, Yong Zhou, Cong Xiao, et al. Application of hydroxyapatite nanoparticles in tumor-associated bone segmental defect. Science Advances. 02 Aug 2019. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1907599, encodeId=d606190e5999a, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat May 16 05:50:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560087, encodeId=6df8156008e6b, content=<a href='/topic/show?id=4ef810169912' target=_blank style='color:#2F92EE;'>#骨支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101699, encryptionId=4ef810169912, topicName=骨支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18f715064805, createdName=lixiaol, createdTime=Mon Aug 12 09:50:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566096, encodeId=74dc1566096ae, content=<a href='/topic/show?id=4ef810169912' target=_blank style='color:#2F92EE;'>#骨支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101699, encryptionId=4ef810169912, topicName=骨支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18f715064805, createdName=lixiaol, createdTime=Mon Aug 12 09:50:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1907599, encodeId=d606190e5999a, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat May 16 05:50:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560087, encodeId=6df8156008e6b, content=<a href='/topic/show?id=4ef810169912' target=_blank style='color:#2F92EE;'>#骨支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101699, encryptionId=4ef810169912, topicName=骨支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18f715064805, createdName=lixiaol, createdTime=Mon Aug 12 09:50:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566096, encodeId=74dc1566096ae, content=<a href='/topic/show?id=4ef810169912' target=_blank style='color:#2F92EE;'>#骨支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101699, encryptionId=4ef810169912, topicName=骨支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18f715064805, createdName=lixiaol, createdTime=Mon Aug 12 09:50:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2019-08-12 lixiaol
  3. [GetPortalCommentsPageByObjectIdResponse(id=1907599, encodeId=d606190e5999a, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat May 16 05:50:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560087, encodeId=6df8156008e6b, content=<a href='/topic/show?id=4ef810169912' target=_blank style='color:#2F92EE;'>#骨支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101699, encryptionId=4ef810169912, topicName=骨支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18f715064805, createdName=lixiaol, createdTime=Mon Aug 12 09:50:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566096, encodeId=74dc1566096ae, content=<a href='/topic/show?id=4ef810169912' target=_blank style='color:#2F92EE;'>#骨支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101699, encryptionId=4ef810169912, topicName=骨支架)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18f715064805, createdName=lixiaol, createdTime=Mon Aug 12 09:50:00 CST 2019, time=2019-08-12, status=1, ipAttribution=)]
    2019-08-12 lixiaol

相关资讯

Adv Sci:中国研究人员开发出新型骨支架

中国一个研究团队开发出一种兼具抗肿瘤和骨再生功能的承力骨替代支架,在动物实验中,不外加化疗药物即能达到良好的治疗及修复效果,将来有望使面临截肢的骨肿瘤患者接受保肢手术治疗,并提高患者的长期生存率。